US Pharma MarketingAbbVie’s Skyrizi combo beats Skyrizi alone in mid-stage Crohn’s trial
At the three-month point, 30.2% of patients treated with ABBV-466 met the primary endpoint of endoscopic remission. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug…
AbbVie’s Skyrizi-based combination therapy for inflammatory bowel disease worked better than Skyrizi alone in a mid-stage trial in Crohn’s disease, the company said Monday.
The new product is codenamed ABBV-466 and combines Skyrizi, an IL-23 ...
Source: Endpoints News